Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of Senaparib in Healthy Subjects
NCT04057729Phase 1Completed
- Sponsor
- IMPACT Therapeutics
- Start
- Jul 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of senaparib in solid tumor (2 arms), sponsored by IMPACT Therapeutics. Primary endpoints: Maximum Plasma Concentration at 2 months, Time to Maximum Plasma Concentration at 2 months and 2 more. Started Jul 2019; status: completed.
02
Drugs
senaparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04057729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04057729.